# US 7,579,148 B2 · Methods and compositions for diagnosing or monitoring autoimmune and chronic inflammatory diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,579,148 B2
- Document ID: US7579148B2
- Status: Granted
- Kind: B2
- Application number: 10/990,298
- Filed: 2004-11-15
- Published: 2007-02-15
- Granted: 2009-08-25
- Earliest claimed: 2001-06-08
- Assignees: Expression Diagnostics, Inc.
- Inventors: Jay Wohlgemuth; Kirk Fry; Robert Woodward; Ngoc Ly
- Web page: https://patentgrep.com/patent/US7579148B2

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/06: Antiasthmatics
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/158: Expression markers
- Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Methods of diagnosing or monitoring an autoimmune or chronic inflammatory disease, particularly SLE in a patient by detecting the expression level of one or more genes or surrogates derived therefrom in the patient are described. Diagnostic oligonucleotides for diagnosing or monitoring chronic inflammatory disease, particularly SLE infection and kits or systems containing the same are also described.

## Claims

### Claim 1

A method of diagnosing or monitoring an autoimmune or chronic inflammatory disease in a patient, comprising detecting the expression level of a nucleic acid in said patient to diagnose or monitor said autoimmune or chronic inflammatory disease in said patient wherein said nucleic acid comprises the nucleotide sequence SEQ ID NO: 151.

### Claim 2 (depends on 1)

The method of claim 1 wherein said autoimmune or chronic inflammatory disease is systemic lupus erythematosis (SLE).

### Claim 3 (depends on 1)

The method of claim 1 wherein said expression level is detected by measuring the RNA level expressed by said nucleic acid.

### Claim 4 (depends on 3)

The method of claim 3, further including isolating RNA from said patient prior to detecting said RNA level expressed by said nucleic acid.

### Claim 5 (depends on 3)

The method of claim 3 wherein said RNA level is detected by PCR.

### Claim 6 (depends on 3)

The method of claim 3 wherein said RNA level is detected by hybridization.

### Claim 7 (depends on 3)

The method of claim 3 wherein said RNA level is detected by hybridization to an oligonucleotide.

### Claim 8 (depends on 7)

The method of claim 7 wherein said oligonucleotide comprises DNA, RNA, cDNA, PNA, genomic DNA, or synthetic oligonucleotides.